Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia Xalcom

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Approvable" letter issued June 2 for combination of Xalatan (latanoprost) and beta blocker timolol (Merck's Timoptic) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers, prostaglandins or other IOP-lowering medications. The application is receiving priority review. Pharmacia's Xalatan is indicated for open-angle glaucoma and ocular hypertensio

You may also be interested in...



COVID-19 Flexibility For Telehealth Payments Should Be Made Permanent, Telemedicine Group Tells CMS

The American Telemedicine Association backed use of more telehealth providers and changes to remote monitoring reimbursements in comments to the US Medicare agency.

STADA Strengthens Specialty Partnership Role Via US Filing

STADA Strengthens Specialty Partnership Role Via US Filing

US Election 2020: Trump’s Sway Over Courts Expected To Linger

Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies, experts tell Medtech Insight.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel